河北医科大学学报 ›› 2025, Vol. 46 ›› Issue (5): 539-547.doi: 10.3969/j.issn.1007-3205.2025.05.008

• • 上一篇    下一篇

顺铂耐药性肺癌荷瘤裸鼠模型的建立与评价

  

  1. 1.北京中医药大学第三附属医院肿瘤血液科,北京 100029;2.Silver Bamboo Health Science LLC,Fairfax 22030;
    3.北京朝阳中西医结合急诊抢救医院妇科,北京100022;4.中国中医科学院中医药信息研究所,北京100700

  • 出版日期:2025-05-25 发布日期:2025-05-23
  • 作者简介:李志明(1991-),男,山西忻州人,北京中医药大学第三附属医院主治医师,医学博士,从事中西医结合防治恶性肿瘤研究。

  • 基金资助:
    国家自然科学基金项目(81973783);北京中医药大学新教师启动基金项目(2022-JYB-XJSJJ-087)

Establishment and evaluation of a nude mouse model of cisplatin-resistant lung cancer

  1. 1.Department of Oncology and Hematology, the Third Affiliated Hospital of Beijing University of 
    Chinese Medicine, Beijing 100029, China; 2.Silver Bamboo Health Science LLC, Fairfax 
    22030, USA; 3.Department of Gynaecology, Emergency Rescue Hospital, 
    Beijing Chaoyang Hospital of Integrated TCM and Western Medicine, 
    Beijing 100022, China; 4.Institute of Information on Traditional 
    Chinese Medicine, China Academy of Chinese Medical 
    Sciences, Beijing 100700, China

  • Online:2025-05-25 Published:2025-05-23

摘要: 目的 建立顺铂耐药性肺癌荷瘤裸鼠模型,并对造模效果进行评价。
方法 体外培养人肺腺癌A549细胞与人肺腺癌顺铂耐药型A549细胞(A549/DDP),接种细胞悬液于裸鼠背部皮下,构建肺癌荷瘤裸鼠模型。分离瘤体细胞,进行原代培养。选择顺铂溶液为实验用药,按照浓度梯度(0.125、0.25、0.5、1、2、4、8、16、32与64 mg/L)依次设立10个组别,分别对A549及A549/DDP细胞进行干预。采用四甲基偶氮唑盐法检测3个时间节点(24 h、48 h与72 h)下的OD值,计算细胞抑制率;获得顺铂的半数抑制浓度(half maximal inhibitory concentration,IC50),确定耐药倍数,验证肺癌模型是否具备顺铂耐药性质。
结果 ①随着时间、浓度的增加,顺铂对A549/DDP细胞的抑制率逐渐升高,组间、时点间、组间·时点间交互作用差异均有统计学意义(P<0.05)。②随着时间、浓度的增加,顺铂对A549细胞的抑制率逐渐升高,组间、时点间差异均有统计学意义(P<0.05);且组间与时点间存在交互作用(P<0.05)。③在相同时间、相同浓度下,顺铂对A549细胞的抑制率明显高于A549/DDP细胞;且组间差异有统计学意义(P<0.05)。④随着时间的增加,顺铂对A549、A549/DDP细胞的IC50值均逐渐降低,组间、时点间差异有统计学意义(P<0.05);且组间与时点间存在交互作用(P<0.05)。⑤干预24 h、48 h与72 h下,获得的耐药倍数分别为12.395±1.209、29.043±2.178、16.902±0.727;组间差异有统计学意义(P<0.05)。均提示细胞高度耐药,其中,48 h耐药性质最佳。
结论 通过皮下接种A549/DDP细胞悬液,可成功构建顺铂耐药性质的肺癌荷瘤裸鼠模型。该模型可为进一步研究耐药发生与演变的生物学机制提供良好的载体。


关键词: 肺肿瘤, 顺铂, 抗药性, 肿瘤

Abstract: Objective To establish a nude mouse model of cisplatin-resistant lung cancer and to evaluate the modeling effect. 
Methods Human lung adenocarcinoma A549 cells and human lung adenocarcinoma cisplatin-resistant A549 cells (A549/DDP) were cultured in vitro, and cell suspensions were inoculated subcutaneously on the back of nude mice to construct a tumor-bearing nude mouse model of lung cancer. Tumor cells were separated and primary culture was performed. Cisplatin solution was selected as the experimental drug, and 10 groups were set up according to concentration gradients (0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32, and 64 mg/L) to intervene in A549 and A549/DD P cells, respectively. MTT assay was used to detect OD values at three time points (24 h, 48 h, and 72 h), to calculate cell inhibition rate. The half maximal inhibitory concentration (IC50) of cisplatin was obtained, to determine the multiples of drug resistance, and to verify whether the lung cancer model had cisplatin resistance properties. 
Results ① With the increase of time and concentration, the inhibition rate of cisplatin on A549/DDP cells gradually increased, showing significant difference of interaction between groups, time points and time points between groups (P<0.05). ②With the increase of time and concentration, the inhibition rate of cisplatin on A549 cells gradually increased, showing significant difference of interaction between groups and between time points (P<0.05); there was an interaction between groups and time points (P<0.05). ③At the same time and concentration, the inhibitory rate of cisplatin on A549 cells was significantly higher than that on A549/DDP cells, showing significant difference between groups (P<0.05). ④With the increase of time, the IC50 of cisplatin on A549 and A549/DDP cells gradually decreased, showing significant difference of interaction between groups and between time points (P<0.05); there was an interaction between groups and time points (P<0.05). ⑤The multiples of drug resistance obtained after intervention for 24 h, 48 h, and 72 h were 12.395±1.209, 29.043±2.178, and 16.902±0.727, respectively; There was a significant difference between the groups (P<0.05). All indicated a high degree of drug resistance of cells, with the optimal resistance observed at 48 h. 
Conclusion A nude mouse model of cisplatin-resistant lung cancer can be successfully constructed by subcutaneous inoculation of A549/DDP cell suspension. This model can provide a good carrier for further studying the biological mechanisms of occurrence and evolution of drug resistance. 

Key words: lung neoplasms, cisplatin, drug resistance, neoplasm